Bowman & Co S.C. Increases Holdings in DexCom, Inc., Brighton Jones LLC Increases Holdings Significantly

Summary

Bowman & Co S.C. increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 64% in Q2, owning 11,566 shares valued at $1.01 million. Brighton Jones LLC increased its stake by 257.7%. Insider sales included EVP Sadie Stern selling 1,466 shares and Director Mark G. Foletta selling 2,750 shares. Analysts have set a consensus rating of ‘Moderate Buy’ with an average target of $99.89. DexCom’s stock opened at $75.58, with a market cap of $29.64 billion.Market Beat

Impact Analysis

So basically, we’re seeing a classic tug-of-war between institutional optimism and technical caution with DexCom. Bowman & Co S.C. and Brighton Jones LLC significantly increased their stakes, which is a strong vote of confidence from institutional investors Market Beat. This is happening even as insiders are selling shares, which typically signals a lack of confidence from those closest to the company. The technical analysis paints a bearish picture with a long-term downtrend and MACD indicating a sell signal . Yet, the stock is trading below the average analyst target, suggesting potential upside if the fundamentals align. The market might be underestimating the institutional conviction here, especially given DexCom’s strong revenue growth and market position in diabetes monitoring Market Beat. I’d watch for any shifts in insider activity or technical indicators that might align with the institutional bullishness. This could be a contrarian play if the technicals start to improve.